Ron Squarer has joined Array BioPharma, a US biopharmaceutical company focused on the discovery and development of small molecule drugs to treat cancer and inflammatory diseases, as chief executive.
Squarer has had a 20-year career in the pharmaceutical industry. Most recently he was chief commercial officer at Hospira, a global pharmaceutical and medical device company. Prior to this, he was Hospira’s senior vice president, global marketing and corporate development.
Squarer joined Hospira from Mayne Pharma, an oncology-focused, global pharmaceutical company, where was senior vice president, global corporate and business development when Mayne was sold to Hospira for US$2bn in 2007.
Earlier, he held management roles at Pfizer and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the US and Europe.
